Axonics Inc. (AXNX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Axonics Inc. (AXNX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

70.98

0.00 (0.00%)

At close: Nov 14, 2024, 9:00 PM

undefined% (undefined)

Bid	n/a
Market Cap	3.63B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.1
PE Ratio (ttm)	-709.8
Forward PE	n/a
Analyst	Hold

Ask	n/a
Volume	0
Avg. Volume (20D)	458,235
Open	undefined
Previous Close	70.98
Day's Range	70.98 - 70.98
52-Week Range	55.09 - 71.05
Beta	undefined

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacra...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 31, 2018

Employees 797

Stock Exchange NASDAQ

Ticker Symbol AXNX

Website https://www.axonics.com

Analyst Forecast

According to 13 analyst ratings, the average rating for AXNX stock is "Hold." The 12-month stock price forecast is $71, which is an increase of 0.03% from the latest price.

Buy 7.69%

Hold 53.85%

Sell 0.00%

Stock Forecasts

News

1 month ago · zacks.com

Boston Scientific Stock Set to Gain From Completion of Axonics Deal

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

2 months ago · zacks.com

Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year...

3 months ago · zacks.com

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.

3 months ago · businesswire.com

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® re...

3 months ago · zacks.com

Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic

AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.

3 months ago · businesswire.com

Axonics Prevails in Patent Infringement Lawsuit with Medtronic

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in ...

5 months ago · zacks.com

Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago...

8 months ago · https://www.defenseworld.net

Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities an...

8 months ago · businesswire.com

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

8 months ago · businesswire.com

Axonics Reports First Quarter 2024 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfu...

9 months ago · reuters.com

FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.

9 months ago · zacks.com

All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago · businesswire.com

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord...

9 months ago · businesswire.com

Axonics Provides Update on Inter Partes Review Proceedings

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two ...

10 months ago · zacks.com

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

10 months ago · businesswire.com

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...

10 months ago · businesswire.com

Axonics Responds to ITC Action by Medtronic

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along...

10 months ago · zacks.com

Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year...

10 months ago · businesswire.com

AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (N...